Get the Stockscreener App
15.07
0.20%
0.03
After Hours:
15.05
-0.02
-0.13%
Overview
News
Price History
Option Chain
Financials
Why CC Down?
Discussions
Forecast
Dividend History
Citigroup Inc stock is traded at $15.07, with a volume of 1.98M.
It is up +0.20% in the last 24 hours and up +3.29% over the past month.
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, paints and coatings, plastics, transportation, semiconductor, and others. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
See More
Previous Close:
$15.04
Open:
$15.4
24h Volume:
1.98M
Relative Volume:
0.79
Market Cap:
$2.27B
Revenue:
$5.82B
Net Income/Loss:
$-411.00M
P/E Ratio:
-5.5082
EPS:
-2.7359
Net Cash Flow:
$154.00M
1W Performance:
-2.65%
1M Performance:
+3.29%
6M Performance:
-15.34%
1Y Performance:
-7.43%
1-Day Range:
$15.01
$15.45
1-Week Range:
$15.01
$15.62
52-Week Range:
$10.44
$28.67
Citigroup Inc Stock (CC) Company Profile
Name
Citigroup Inc
Sector
Industry
Phone
302 773 1000
Address
1007 MARKET STREET, WILMINGTON, DE
Compare CC vs JPM, BAC, HSBC, RY, WFC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CC
Citigroup Inc
|
15.07 | 2.26B | 5.82B | -411.00M | 154.00M | -2.7359 |
JPM
Jpmorgan Chase Co
|
353.56 | 942.89B | 297.42B | 64.78B | 148.32B | 23.34 |
BAC
Bank Of America Corp
|
62.56 | 438.24B | 194.43B | 33.77B | 64.54B | 4.3483 |
HSBC
Hsbc Holdings Plc Adr
|
103.70 | 359.98B | 133.80B | 21.76B | 105.99B | 6.0511 |
RY
Royal Bank Of Canada
|
205.98 | 286.31B | 99.69B | 16.04B | 26.84B | 11.15 |
WFC
Wells Fargo Co
|
89.45 | 271.16B | 128.92B | 22.97B | -2.35B | 6.8796 |
Citigroup Inc Stock (CC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Upgrade | Mizuho | Neutral → Outperform |
| Jan-28-25 | Initiated | Truist | Buy |
| Jul-09-24 | Upgrade | UBS | Neutral → Buy |
| Jun-07-24 | Initiated | Mizuho | Neutral |
| Apr-09-24 | Upgrade | BMO Capital Markets | Underperform → Outperform |
| Mar-05-24 | Downgrade | UBS | Buy → Neutral |
| Feb-29-24 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Dec-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-22-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-24-23 | Upgrade | UBS | Neutral → Buy |
| Jan-11-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-01-22 | Initiated | Credit Suisse | Underperform |
| Oct-13-22 | Initiated | Goldman | Neutral |
| Oct-05-22 | Downgrade | Argus | Buy → Hold |
| Jun-14-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-10-21 | Initiated | Wolfe Research | Outperform |
| Jun-09-21 | Upgrade | Goldman | Neutral → Buy |
| May-20-21 | Initiated | BofA Securities | Buy |
| May-06-21 | Upgrade | Argus | Hold → Buy |
| Jan-08-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-04-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Nov-30-20 | Initiated | Alembic Global Advisors | Overweight |
| Mar-23-20 | Downgrade | Jefferies | Buy → Hold |
| Feb-14-20 | Upgrade | CFRA | Buy → Strong Buy |
| Nov-06-19 | Upgrade | CFRA | Hold → Buy |
| Aug-20-19 | Upgrade | Susquehanna | Neutral → Positive |
| Aug-09-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-19 | Downgrade | Argus | Buy → Hold |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jul-12-19 | Downgrade | Citigroup | Buy → Neutral |
| May-06-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-15-19 | Upgrade | SunTrust | Hold → Buy |
| Feb-19-19 | Downgrade | Susquehanna | Positive → Neutral |
| Jan-08-19 | Initiated | HSBC Securities | Buy |
| Jan-04-19 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-18 | Downgrade | Citigroup | Buy → Neutral |
| Jul-18-18 | Initiated | RBC Capital Mkts | Outperform |
| Jan-30-18 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-06-17 | Downgrade | Goldman | Buy → Neutral |
| Aug-07-17 | Upgrade | UBS | Sell → Neutral |
View All
Citigroup Inc Stock (CC) Latest News
Citigroup (C) Completed a Weekend Tokenized-Dollar Transfer. Can the Network Scale? - Yahoo Finance
SIG Maintained by Citigroup -- Price Target Raised to $140 - GuruFocus
Sana Biotechnology at citigroup’s biopharma back to school summit 2026: diabetes push - Investing.com
BioMarin at Citi summit: voxzogo drives growth as pipeline widens By Investing.com - Investing.com Canada
SYK Maintained by Citigroup -- Price Target Lowered to $360 - GuruFocus
Transcript : Novavax, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-10-2026 10 - marketscreener.com
Form FWP Citigroup Global Markets Filed by: Citigroup Global Markets Holdings Inc. - StreetInsider
Kymera Therapeutics at citigroup summit: oral immunology push gains pace By Investing.com - Investing.com India
SpyGlass Pharma at Citigroup summit: glaucoma lens nears phase iii By Investing.com - Investing.com Canada
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
Jazz Pharmaceuticals at citigroup summit: rare-disease push gains pace By Investing.com - Investing.com India
Roivant at Citi summit: cash-rich biotech leans on three pillars - Investing.com Canada
MercadoLibre Secures $1.0 Billion 5.850% Notes Due 2036 With BofA, Citi, Goldman and Others - TradingView
Form 424B2 CITIGROUP INC - StreetInsider
Acumen at Citi biopharma summit: bets on oligomers and brain delivery - Investing.com
C Pushes Tokenized Deposits Deeper Into Asia With Japan Expansion - TradingView
Citigroup Inc. stock gains as recent earnings beat expectations - ad-hoc-news.de
Why Is Citigroup (NYES:C) Expanding in China Brokerage? - Kalkine Media
Citigroup (C) Gains on Turnaround Momentum - Yahoo Finance
Form 8K Citigroup For: 10 September By Investing.com - Investing.com Canada
Citigroup Adjusts Price Target on Cooper to $60 From $80, Keeps Neutral Rating - marketscreener.com
4 Thriving Investment Bank Behemoths to Buy With Attractive Valuation - TradingView
Citigroup Upgrades UiPath (NYSE:PATH) to "Strong-Buy" - MarketBeat
Nordnet AB And Citigroup Inc. Launch Research Portal Giving Savers Access To Research - marketscreener.com
Citigroup Inc. $C Shares Acquired by Tidal Investments LLC - MarketBeat
Citigroup Adjusts Price Target on Boston Scientific to $57 From $61, Keeps Buy Rating - marketscreener.com
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Citigroup Inc. $C Position Trimmed by National Pension Service - MarketBeat
WINTON GROUP Ltd Has $11.44 Million Holdings in Citigroup Inc. $C - MarketBeat
Integrated Wealth Concepts LLC Sells 10,009 Shares of Citigroup Inc. $C - MarketBeat
Engineers Gate Manager LP Lowers Stake in Citigroup Inc. $C - MarketBeat
BlueCrest Capital Management Ltd Reduces Holdings in Citigroup Inc. $C - MarketBeat
Citigroup stock heads into the open after a 1.0 percent gain - ad-hoc-news.de
Citigroup Becomes Substantial Shareholder in Lotus Resources with 5.08% Stake - Kalkine
BioAge at Citi biopharma summit: pivot to eye disease and new targets - Investing.com Canada
Citigroup's Private Bank Hires Radzinski From Bank Of America - marketscreener.com
Veradermics at citigroup summit: oral hair-loss drug nears key data - Investing.com
Citi Private Bank hires Radzinski from Bank of America - WTVB
Akamai Technologies Jumps 5.3% After Citigroup Maintains Neutral - AlphaStreet
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03:00 PM - marketscreener.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Citigroup : Citi First Quarter, Second Quarter, Third Quarter and Fourth Quarter 2027 Earnings Calls - marketscreener.com
LULU Maintained by Citigroup -- Price Target Lowered to $117.00 - GuruFocus
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com India
Cytokinetics at citigroup summit: hcm expansion drives growth hopes - Investing.com
Transcript : Protagonist Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset - Investing.com
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Ollie’s Bargain Outlet Holdings Drops 5.7% After Citigroup Maintains Buy - AlphaStreet
Learn Why The Bull Case For Citi Stock Could Change Following China Brokerage Approval - simplywall.st
Citigroup Inc Stock (CC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):